Mallo M.,Hospital del Mar |
Mallo M.,Spanish Hematological Cytogenetics Working Group |
Mallo M.,Spanish MDS Registry Group |
Mallo M.,Autonomous University of Barcelona |
And 16 more authors.
Leukemia Research | Year: 2011
The clone size has been postulated as a prognostic factor in myelodysplastic syndromes (MDS), though it has not been studied systematically. We tested its impact (<100% vs. 100%) in a population of 216 MDS with chromosome 7 abnormalities (-7/7q-) (n=84), trisomy 8 (n=99), 20q deletion (n=28) and loss of Y chromosome (n=26). Focusing on the survival the bad prognosis of -7/7q- was independent of the clone size (9.3 vs. 5.0 months, P=0.188, not significant) but trisomy 8 cases with 100% aberrant metaphases did reveal a worse prognosis (13.9 vs. 5.9 months, P=0.003). © 2011 Elsevier Ltd.